We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

19 hedge funds and large institutions have $448K invested in Biolase, Inc. in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

12% more funds holding

Funds holding: 17 → 19 (+2)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

88% less capital invested

Capital invested by funds: $3.59M → $448K (-$3.14M)

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Prudential Financial
Prudential Financial
New Jersey
+$60.7K
2
HF
HRT Financial
New York
+$43.6K
3
Renaissance Technologies
Renaissance Technologies
New York
+$35K
4
VF
Virtu Financial
New York
+$34.4K
5
TSS
Two Sigma Securities
New York
+$16K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.7M
2
EIM
Essex Investment Management
Massachusetts
-$152K
3
PCM
Perkins Capital Management
Minnesota
-$124K
4
Citadel Advisors
Citadel Advisors
Florida
-$43K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$19.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
– -$43K -175 Closed
1
2

BIOL Hedge Fund Activity: Q4 2022 in Review

19 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2022, worth a combined $448K — down 88% from $3.59M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIOL positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Prudential Financial, opening a new position worth an estimated $60.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.7M sold.

  • 19 institutional investors held Biolase, Inc. (BIOL) as of Q4 2022, up from 17 in Q3 2022.
  • Funds reported $448K of Biolase, Inc. stock for Q4 2022, down 88% quarter-over-quarter.
  • 6 funds opened new Biolase, Inc. positions in Q4 2022 and 4 closed out, a net change of +2 holders.
  • The largest Biolase, Inc. buyer in Q4 2022 was Prudential Financial, an estimated $60.7K added.
  • The largest Biolase, Inc. seller in Q4 2022 was Armistice Capital, an estimated $1.7M sold.

Based on aggregated 13F filings for Q4 2022.